Volume 96 Issue 8 | p. 14 | Concentrates
Issue Date: February 19, 2018

Bristol-Myers strikes huge deal with Nektar

By Ryan Cross
Department: Business
Keywords: Oncology, immuno-oncology, cancer, immunotherapy, Nektar, BMS, Bristol-Myers Squibb, interleukin-2, CD-122

Bristol-Myers Squibb will give Nektar Therapeutics $1.85 billion up front and potentially another $1.78 billion to jointly develop Nektar’s protein-based cancer immunotherapy NKTR-214. BMS is betting on combining NKTR-214, currently in a Phase I/II trial, with its two approved antibody checkpoint inhibitors, Opdivo and Yervoy. Trials are planned for nine tumor types. NKTR-214 is a prodrug of the immune-system-activating cytokine interleukin-2, already a cancer treatment. The drug binds the interleukin-2 receptor, leading to stimulated immune cells that target tumors.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment